Resolution Therapeutics
Biotechnology ResearchScotland, United Kingdom51-200 Employees
Resolution Therapeutics is a clinical-stage biotechnology company developing regenerative macrophage therapy to treat inflammatory and fibrotic diseases. The company was spun out of the Forbes Lab at University of Edinburgh's Centre for Regenerative Medicine in 2020 and is backed by Syncona. Our initial focus is in end-stage liver disease (advanced cirrhosis). It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, only supportive therapies are currently available. For patients with end-stage liver disease the only therapeutic option is liver transplantation, a complex surgical procedure limited by complications and a shortage of donors. At Resolution, we are developing a first-in-class product to treat patients at risk of liver decompensation, thus helping them avoid the need for a liver transplant.
1-888-653-2347 
support@leadiq.com 
